论文部分内容阅读
吉西他滨(GEM)作为一种新型嘧啶类抗代谢剂,对多种实体瘤尤其是非小细胞肺癌、胰腺癌、乳腺癌、膀胱癌等具有独特的抗瘤活性。它在非小细胞肺癌和胰腺癌治疗中的地位已被确定,临床应用显示其不良反应轻微,耐受性好,近年来被广泛应用于乳腺癌,联合用药疗效好,且不良反应可控制,使用其单剂或含GEM联合方案救治晚期乳腺癌取得了令人注目的临床效果。本文对晚期乳腺癌患者使用GEM及联合方案治疗的疗效和安全性予以综述。
Gemcitabine (GEM), as a new pyrimidine antimetabolite, has unique anti-tumor activity against a variety of solid tumors, especially non-small cell lung cancer, pancreatic cancer, breast cancer and bladder cancer. Its status in the treatment of non-small cell lung cancer and pancreatic cancer has been identified, clinical application showed mild adverse reactions, tolerability is good, in recent years has been widely used in breast cancer, combination therapy is good, and adverse reactions can be controlled, The use of its single or GEM-containing regimen for the treatment of advanced breast cancer has achieved remarkable clinical results. This article reviews the efficacy and safety of GEM and combination regimens in patients with advanced breast cancer.